Supernus Pharmaceuticals, Inc. (SUPN) Stock Analysis

Supernus Pharmaceuticals is a U.S.-focused specialty CNS biopharmaceutical company whose commercial transition is increasingly visible in reported results. Its growth portfolio comprises Qelbree for ADHD, GOCOVRI for Parkinson’s dyskinesia and off episodes, ZURZUVAE for postpartum depression, and ONAPGO for advanced Parkinson’s motor fluctuations, while Trokendi XR and Oxtellar XR face generic erosion. **Q2 2026 total revenue rose 32.4% to $219.1 million, and growth-product revenue increased 52.0% to $175.7 million.** Qelbree sales were $89.2 million, ZURZUVAE collaboration revenue was $35.4 million, GOCOVRI sales were $37.6 million, and ONAPGO sales reached $13.5 million. Management raised 2026 revenue guidance to $860 million–$890 million and adjusted operating earnings guidance to $150 million–$180 million. GAAP results were distorted by a $54.9 million non-cash APOKYN impairment, producing a $58.4 million net loss, while adjusted operating earnings remained $31.2 million. The stock trades near $41.49 at approximately 2.57x EV/LTM sales, below cited specialty-pharma peer ranges of 3.0x–4.7x, with a $61.75 consensus target. Near-term catalysts are ONAPGO supply resolution and the proposed Indivior merger, which targets $2.2 billion of combined revenue and $125 million of annual synergies.